BI believes that MAG45 is a true integrator which can help them to build a stable supply chain, a good warehouse management system with a sophisticated logistic setup and an efficient and lean process.
MAG45 will enable standardisation of processes and products with support of MAG45 on-site personnel. Project preparations were initiated in April and the project roll out started when the contract was signed in June 2018.
Fred Cannon, Plant Manager Boehringer Ingelheim: “I believe MAG45 can help BI Taizhou to build up a perfect MRO management system from the beginning. This site will be used as a pilot among all BI factories.”
Victor Roos, Commercial Director MAG45: “In partnering with BI, our aim is to introduce new and improved ways of working that focus on long-term, continuous improvement. We are looking forward to create value for Boehringer Ingelheim by implementing our tailored MRO solutions and creating a reference site”.
Boehringer Ingelheim - Plant Taizhou
About Boehringer Ingelheim
Improving the health and quality of life of patients is the goal of the research-driven pharmaceutical company Boehringer Ingelheim. The focus in doing so is on diseases for which no satisfactory treatment option exists to date. The company therefore concentrates on developing innovative therapies that can extend patients' lives. In animal health, Boehringer Ingelheim stands for advanced prevention.
Family-owned since it was established in 1885, Boehringer Ingelheim is one of the pharmaceutical industry's top 20 companies. Some 50,000 employees create value through innovation daily for the three business areas human pharmaceuticals, animal health and biopharmaceuticals. In 2017, they achieved net sales of around 18.1 billion euros.
More information: www.boehringer-ingelheim.com.